STOCK TITAN
  1. Home
  2. News
  3. CYTH

Cyclo Therapeutics Inc - CYTH STOCK NEWS

Welcome to our dedicated news page for Cyclo Therapeutics (Ticker: CYTH), a resource for investors and traders seeking the latest updates and insights on Cyclo Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cyclo Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cyclo Therapeutics's position in the market.

News
Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
Rhea-AI Summary
Cyclo Therapeutics, Inc. (CYTH) reports progress in Phase 3 study for Niemann-Pick Disease Type C1 treatment, aligns with FDA, and ends 2023 with $9.2 million in cash. The company aims to provide earlier access to efficacious treatments, bolster cash position, and extend runway through clinical milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
earnings
-
News
Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease
Rhea-AI Summary
Cyclo Therapeutics, Inc. (CYTH) secures U.S. Patent for treating Alzheimer's disease with Trappsol® Cyclo™, aiming to address the unmet medical need. The company is dedicated to developing life-changing medicines through innovation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.32%
Tags
none
-
News
Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer’s Disease from the U.S. Patent and Trademark Office
Rhea-AI Summary
Cyclo Therapeutics, Inc. (CYTH) received a Notice of Allowance from the USPTO for its U.S. Patent Application titled 'Methods for Treating Alzheimer’s Disease.' The CEO, N. Scott Fine, sees this as a significant milestone for the company's Alzheimer's disease asset and a valuable addition to its patent estate. The company remains hopeful about the potential of Trappsol® Cyclo™ in addressing the urgent need for innovative therapeutic solutions for early onset Alzheimer's disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.51%
Tags
none
News
Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.
Rhea-AI Summary
Cyclo Therapeutics, Inc. (CYTH) and Applied Molecular Transport Inc. (AMTI) have completed a merger, forming a combined company operating as Cyclo Therapeutics with a focus on advancing Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1). The cash runway has been extended into 2H 2024 with approximately $11.0 million cash on hand to fund operations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
-
News
Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1
Rhea-AI Summary
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) announced positive FDA feedback from its Type C meeting, leading to a direction for the comparative interim analysis of its ongoing pivotal Phase 3 study, TransportNPC™, for the treatment of Niemann-Pick Disease Type C1 (NPC1). The FDA aligned with the company's proposal to continue with the Phase 3 96-week study, but change the timing of the planned comparative interim analysis to execute data readout in Q1 2025. The ongoing study is a randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the safety, tolerability, and efficacy of Trappsol® Cyclo™ in patients with NPC1. The Company's clinical data provided suggestive evidence of potential therapeutic benefit, and the FDA feedback allows for continued advancement of the program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags
none
-
News
Cyclo Therapeutics to Present at the 20th Annual WORLDSymposium™ 2024
Rhea-AI Summary
Cyclo Therapeutics, Inc. (CYTH) to present pivotal Phase 3 global study on Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 at the 20th Annual WORLDSymposium™
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.82%
Tags
conferences
News
Cyclo Therapeutics Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) reported strong enrollment in its pivotal Phase 3 global study evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (“NPC1”). The company is also on track to close a merger with Applied Molecular Transport, Inc. before the year ends. Additionally, they have taken steps to strengthen their balance sheet and extend their cash position.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.53%
Tags
earnings
-
News
Cyclo Therapeutics Announces Early Exercise of Warrants by Board Members, Management and a Significant Shareholder Resulting in Cash Proceeds of $2.4 Million
Rhea-AI Summary
Cyclo Therapeutics has entered into a securities purchase agreement with accredited investors to raise $2.36 million in a private offering. The investors exercised their original warrants and received new warrants with an exercise price of $0.95 per share. The company issued new warrants to purchase a total of 3,655,694 shares of common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.45%
Tags
management
-
News
Cyclo Therapeutics to Present at 8th Annual Dawson James Conference
Rhea-AI Summary
Cyclo Therapeutics to present at 8th Annual Dawson James Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.17%
Tags
conferences
News
Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement
Rhea-AI Summary
Cyclo Therapeutics and Applied Molecular Transport have entered into a merger agreement, forming Cyclo Therapeutics, Inc. The combined company will focus on advancing Trappsol Cyclo for the treatment of Niemann-Pick Disease Type C1 (NPC1). The closing of the merger is expected to result in approximately $13.7 million in cash for operations until 2H 2024. Upcoming milestones include completing enrollment in a pivotal Phase 3 clinical trial, reporting top-line data, and preparing for NDA submission.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
acquisition
Stock CYTH logo
Cyclo Therapeutics Inc

Nasdaq:CYTH

CYTH Rankings

#4916 Ranked by Market Cap
#4676 Ranked by Stock Gains
N/A Ranked by Dividends

CYTH Stock Data

36.18M
15.87M
39.48%
9.76%
0.16%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Gainesville

About CYTH

cyclodextrin technologies development, inc. (ctd), the "company"​, was organized as a florida corporation on august 9, 1990 with operations beginning july, 1992. in may of 1994 the company became a fully reporting public company listed on the otc bb under the symbol ctdi. in 2000, the company altered its corporate structure to a holding company with subsidiary companies. the otc bb symbol was changed to ctdh. ctd holdings, inc. (the "company"​) was originally formed to market and sell cyclodextrins and related products to the food, pharmaceutical, and other industries; it also provided consulting services related to cyclodextrin technology. ctdh, as a holding company, will acquire, create, and invest in companies that will develop, market, and/or sell products containing cyclodextrins. the company currently operates four wholly owned subsidiaries: ctd, inc.; nanosonic products, inc.; sphingo biotech, inc.; and ferrazo environmental technologies, inc.